LEF1 and COVID-19: The expression of Lymphoid Enhancer Binding Factor 1-antisense 1 (LEF1-AS1), for example, has recently been associated with in-hospital mortality following SARS-CoV-2 infection [13] and could be used as a biomarker of disease severity in COVID-19 patients [14].